ABSTRACT
Implementation is underway for many of these programs, and there are descriptions of activities elsewhere in this symposium. The Board recognizes that in dealing with the complications of a chronic disease like diabetes, many years of intense effort will be needed before significant results may be appreciated. Progress will be monitored regularly by the Surveillance Council and SCDCP/DHEC, and modifications of the plan will be made by the Board at intervals after review of the data. We are optimistic that over the next decade, this system will make a significant impact to reduce mortality, morbidity, and costs of diabetes, and the result will be an increased quality of life for people affected by diabetes in South Carolina.
Subject(s)
Diabetes Mellitus , Legislation, Medical , Diabetes Mellitus/prevention & control , Governing Board , Humans , Program Development , Schools, Medical , South CarolinaSubject(s)
Hypogonadism/blood , Hypopituitarism/blood , Steroids/blood , Testosterone/therapeutic use , Adrenocorticotropic Hormone , Androgens/blood , Humans , Hypogonadism/complications , Hypogonadism/drug therapy , Hypopituitarism/drug therapy , Male , Olfaction Disorders/complications , Pregnenolone/blood , SyndromeABSTRACT
Two patients presented with the galactorrhea-amenorrhea syndrome. One patient had previously had parathyroid hyperplasia and the other an insulinoma. Preoperative evaluation of each patient revealed hyperprolactinemia and radiological evidence of an abnormal sella turcica. Pituitary adenomas were identified and removed at surgery. Immunostaining techniques confirmed the presence of prolactin-containing cells in both tumors. We propose that prolactin-secreting tumors be considered as part of the MEN-I syndrome, and that patients presenting with the galactorrhea-amenorrhea syndrome be screened and followed sequentially for evidence of other endocrine neoplasia.